Oncology Nursing Society Congress

Daratumumab plus lenalidomide maintenance improved clinical outcomes vs lenalidomide monotherapy in multiple myeloma after transplant.

Apalutamide reduced the risk of death by over 20% vs enzalutamide and abiraterone acetate, respectively, in metastatic castration-sensitive prostate cancer.

D-VRd has the potential to significantly improve clinical outcomes in transplant-ineligible or -deferred patients with newly diagnosed multiple myeloma.

Treatment with cilta-cel led to improvements across several QOL subscales compared with SOC therapy in patients with lenalidomide-refractory myeloma.

A retrospective study found that interventions for patients experiencing grade 2 vs 3 blinatumomab-associated ICANS were not consistently implemented.

Daratumumab reduced the risk of disease progression or death vs active monitoring in high-risk smoldering multiple myeloma.

Cancer clinical trial education is valuable and may promote current and future participation.

Early infection risk following cilta-cel infusion in patients with multiple myeloma emphasizes the importance of monitoring for treatment-emergent infections.

Educating patients and health care providers about BiTE-associated CRS and ICANS increases comfort levels with giving these agents in outpatient settings.

The association between greater hematologic AEs and increased OS necessitates early receipt of G-CSF after NALIRIFOX infusion for patients with PDAC.

Social factors including financial needs and stress caused increased levels of psychoneurological symptoms in breast cancer survivors.

A clinical trial steering committee from the Mount Sinai Health System helped integrate therapeutic clinical trials into the SOC for patients with cancer.

Diarrhea is common in patients with PDAC treated with NALIRIFOX and can be proactively managed or mitigated to potentially improve survival outcomes.

Subcutaneous nivolumab demonstrated comparable efficacy, safety, and tolerability to IV nivolumab in advanced clear cell renal cell carcinoma.

ARANOTE data underscore that combining darolutamide with ADT benefits patients with mHSPC irrespective of whether they also receive docetaxel.

A study identified individual and non-individual factors as barriers to breast cancer screening for women in Jordan.

Niraparib was found to maintain or improve health-related quality of life in patients with advanced or metastatic castration-resistant prostate cancer, according to data from the final analysis of the phase 2 GALAHAD trial.

The addition of apalutamide to androgen deprivation therapy was not found to significantly reduce health-related quality of life or increase patient-reported adverse effect burden in patients with metastatic castration-sensitive prostate cancer enrolled to the phased 3 TITAN trial.

Although it is not considered to be a standard of care for patients with indolent non-Hodgkin lymphoma, very low dose radiation therapy was found to have efficacy in the palliative setting and to allow for retreatment to the same field when needed.

The time-limited combination of ublituximab and umbralisib plus ibrutinib resulted in an undetectable minimal residual disease rate of 77% in patients with chronic lymphocytic leukemia, according to findings from a phase 2 trial (NCT04016805)

When chemotherapy involves tricky infusion timing, patients are routinely admitted to hospitals to receive their treatments. But what would happen if these drugs could be administered successfully on an outpatient basis?

West Cancer Center researchers developed a best nursing practice protocol for titration of fentanyl sublingual spray, which is the most recently approved transmucosal immediate-release fentanyl formulation.

Researchers at the Rutgers Cancer Institute of New Jersey are testing the possibility of sending treatment drugs directly to the kidney in patients with upper urinary tract urothelial carcinoma.

When oncology nurses move proactively to learn more about and use proven effective green-lighted interventions like exercise and muscle relaxation in their daily practice, it can go a long way.

A multidisciplinary team led by oncology nurses can reduce both hospitalization and treatment breaks for patients with head and neck cancer.

Cancer doesn’t discriminate, but that doesn’t mean the healthcare system won’t. This proves to be even more true for the lesbian, gay, bisexual and transgender community.

Lots of people take their work home with them, but Lynne Malestic, RN, has given the idea new meaning.

Developing a skin rash as a result of EGFR-inhibitor targeted therapy often signals that the drug is working, but for patients who experience these serious dermatologic adverse events, it may become so intolerable that they will scale back or even discontinue anticancer medications that could prolong their survival.

With the growing use of oral therapies in cancer care, it is crucial that oncology nurses are using a systematic approach to assess and improve adherence, according to Whitney Perry, APRN, AOCNP.

The possibility that hospitalized cancer patients will fall is an ongoing concern among the medical professionals who care for them.